In silico profiling of neem limonoids and gut microbiome metabolites for Alzheimer’s therapeutics: targeted inhibition of BACE1 and elucidation of intricate molecular crosstalk with tau oligomers, and bacterial gingipains
Abstract Alzheimer’s disease (AD) is characterized by the accumulation of amyloid beta plaques and neurofibrillary tangles composed of hyperphosphorylated tau protein. This study computationally investigated natural neem compounds (limonoids) and gut microbiome metabolites for their inhibitory poten...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-04-01
|
| Series: | Discover Applied Sciences |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s42452-025-06821-9 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850187377408999424 |
|---|---|
| author | Oluwaseun E. Agboola Zainab A. Ayinla Samuel S. Agboola Esther Y. Omolayo Abimbola E. Fadugba Othuke B. Odeghe Oluranti E. Olaiya Babatunji E. Oyinloye |
| author_facet | Oluwaseun E. Agboola Zainab A. Ayinla Samuel S. Agboola Esther Y. Omolayo Abimbola E. Fadugba Othuke B. Odeghe Oluranti E. Olaiya Babatunji E. Oyinloye |
| author_sort | Oluwaseun E. Agboola |
| collection | DOAJ |
| description | Abstract Alzheimer’s disease (AD) is characterized by the accumulation of amyloid beta plaques and neurofibrillary tangles composed of hyperphosphorylated tau protein. This study computationally investigated natural neem compounds (limonoids) and gut microbiome metabolites for their inhibitory potential against key AD targets. Molecular docking analyses were performed on approximately 200 neem phytochemicals and 9 microbial metabolites against beta-secretase 1 (BACE1), gingipain cysteine protease, and tau oligomerization receptors using AutoDock. BBB permeability was computationally evaluated using six molecular descriptors: molecular weight, LogP, hydrogen bond acceptors/donors, polar surface area, and rotatable bonds, categorizing compounds as highly or poorly BBB permeable based on established predictive criteria. The results revealed superior binding affinities of limonoids, notably Rutin (− 9.642 kcal/mol), 7-benzoylnimbocinol (− 9.706 kcal/mol), and tirucallol (− 9.488 kcal/mol) against BACE1, gingipain protease, and tau oligomerization receptors, respectively. These compounds exhibited key interactions through hydrogen bonding with Gly34, Asn233 (rutin-BACE1), Lys311, and Asn363 (7-benzoylnimbocinol-gingipain) and hydrophobic interactions with Ile40 and Ile48 (tirucallol-tau). While these limonoids demonstrated binding affinities exceeding melatonin by > 30%, their BBB permeability profiles necessitate sophisticated delivery strategies. Among gut microbiome metabolites, melatonin showed consistent binding across all targets (− 7.079 to − 8.452 kcal/mol). These findings establish limonoids’ superiority over gut microbiome metabolites and highlight their therapeutic potential as multi-target inhibitors in AD pathology, warranting investment in nanocarrier systems for optimizing BBB penetration. |
| format | Article |
| id | doaj-art-bc9380d6d6434deea1b010a439d1a410 |
| institution | OA Journals |
| issn | 3004-9261 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Springer |
| record_format | Article |
| series | Discover Applied Sciences |
| spelling | doaj-art-bc9380d6d6434deea1b010a439d1a4102025-08-20T02:16:06ZengSpringerDiscover Applied Sciences3004-92612025-04-017411410.1007/s42452-025-06821-9In silico profiling of neem limonoids and gut microbiome metabolites for Alzheimer’s therapeutics: targeted inhibition of BACE1 and elucidation of intricate molecular crosstalk with tau oligomers, and bacterial gingipainsOluwaseun E. Agboola0Zainab A. Ayinla1Samuel S. Agboola2Esther Y. Omolayo3Abimbola E. Fadugba4Othuke B. Odeghe5Oluranti E. Olaiya6Babatunji E. Oyinloye7Institute of Drug Research and Development, S.E Bogoro Center, Afe Babalola UniversityDepartment of Biology, University of WaterlooDepartment of Pharmacology and Toxicology, Afe Babalola UniversityDepartment of Biological Sciences, Afe Babalola UniversityDepartment of Biological Sciences, Afe Babalola UniversityDepartment of Medical Biochemistry, Faculty of Basic Medical Sciences, Delta State UniversityDepartment of Medical Biochemistry, College of Medicine and Health Sciences, ABUADInstitute of Drug Research and Development, S.E Bogoro Center, Afe Babalola UniversityAbstract Alzheimer’s disease (AD) is characterized by the accumulation of amyloid beta plaques and neurofibrillary tangles composed of hyperphosphorylated tau protein. This study computationally investigated natural neem compounds (limonoids) and gut microbiome metabolites for their inhibitory potential against key AD targets. Molecular docking analyses were performed on approximately 200 neem phytochemicals and 9 microbial metabolites against beta-secretase 1 (BACE1), gingipain cysteine protease, and tau oligomerization receptors using AutoDock. BBB permeability was computationally evaluated using six molecular descriptors: molecular weight, LogP, hydrogen bond acceptors/donors, polar surface area, and rotatable bonds, categorizing compounds as highly or poorly BBB permeable based on established predictive criteria. The results revealed superior binding affinities of limonoids, notably Rutin (− 9.642 kcal/mol), 7-benzoylnimbocinol (− 9.706 kcal/mol), and tirucallol (− 9.488 kcal/mol) against BACE1, gingipain protease, and tau oligomerization receptors, respectively. These compounds exhibited key interactions through hydrogen bonding with Gly34, Asn233 (rutin-BACE1), Lys311, and Asn363 (7-benzoylnimbocinol-gingipain) and hydrophobic interactions with Ile40 and Ile48 (tirucallol-tau). While these limonoids demonstrated binding affinities exceeding melatonin by > 30%, their BBB permeability profiles necessitate sophisticated delivery strategies. Among gut microbiome metabolites, melatonin showed consistent binding across all targets (− 7.079 to − 8.452 kcal/mol). These findings establish limonoids’ superiority over gut microbiome metabolites and highlight their therapeutic potential as multi-target inhibitors in AD pathology, warranting investment in nanocarrier systems for optimizing BBB penetration.https://doi.org/10.1007/s42452-025-06821-9Azadirachta indicaAlzheimer’s diseaseAmyloid cascadeGingipain proteasesTau oligomerizationGut microbiome metabolites |
| spellingShingle | Oluwaseun E. Agboola Zainab A. Ayinla Samuel S. Agboola Esther Y. Omolayo Abimbola E. Fadugba Othuke B. Odeghe Oluranti E. Olaiya Babatunji E. Oyinloye In silico profiling of neem limonoids and gut microbiome metabolites for Alzheimer’s therapeutics: targeted inhibition of BACE1 and elucidation of intricate molecular crosstalk with tau oligomers, and bacterial gingipains Discover Applied Sciences Azadirachta indica Alzheimer’s disease Amyloid cascade Gingipain proteases Tau oligomerization Gut microbiome metabolites |
| title | In silico profiling of neem limonoids and gut microbiome metabolites for Alzheimer’s therapeutics: targeted inhibition of BACE1 and elucidation of intricate molecular crosstalk with tau oligomers, and bacterial gingipains |
| title_full | In silico profiling of neem limonoids and gut microbiome metabolites for Alzheimer’s therapeutics: targeted inhibition of BACE1 and elucidation of intricate molecular crosstalk with tau oligomers, and bacterial gingipains |
| title_fullStr | In silico profiling of neem limonoids and gut microbiome metabolites for Alzheimer’s therapeutics: targeted inhibition of BACE1 and elucidation of intricate molecular crosstalk with tau oligomers, and bacterial gingipains |
| title_full_unstemmed | In silico profiling of neem limonoids and gut microbiome metabolites for Alzheimer’s therapeutics: targeted inhibition of BACE1 and elucidation of intricate molecular crosstalk with tau oligomers, and bacterial gingipains |
| title_short | In silico profiling of neem limonoids and gut microbiome metabolites for Alzheimer’s therapeutics: targeted inhibition of BACE1 and elucidation of intricate molecular crosstalk with tau oligomers, and bacterial gingipains |
| title_sort | in silico profiling of neem limonoids and gut microbiome metabolites for alzheimer s therapeutics targeted inhibition of bace1 and elucidation of intricate molecular crosstalk with tau oligomers and bacterial gingipains |
| topic | Azadirachta indica Alzheimer’s disease Amyloid cascade Gingipain proteases Tau oligomerization Gut microbiome metabolites |
| url | https://doi.org/10.1007/s42452-025-06821-9 |
| work_keys_str_mv | AT oluwaseuneagboola insilicoprofilingofneemlimonoidsandgutmicrobiomemetabolitesforalzheimerstherapeuticstargetedinhibitionofbace1andelucidationofintricatemolecularcrosstalkwithtauoligomersandbacterialgingipains AT zainabaayinla insilicoprofilingofneemlimonoidsandgutmicrobiomemetabolitesforalzheimerstherapeuticstargetedinhibitionofbace1andelucidationofintricatemolecularcrosstalkwithtauoligomersandbacterialgingipains AT samuelsagboola insilicoprofilingofneemlimonoidsandgutmicrobiomemetabolitesforalzheimerstherapeuticstargetedinhibitionofbace1andelucidationofintricatemolecularcrosstalkwithtauoligomersandbacterialgingipains AT estheryomolayo insilicoprofilingofneemlimonoidsandgutmicrobiomemetabolitesforalzheimerstherapeuticstargetedinhibitionofbace1andelucidationofintricatemolecularcrosstalkwithtauoligomersandbacterialgingipains AT abimbolaefadugba insilicoprofilingofneemlimonoidsandgutmicrobiomemetabolitesforalzheimerstherapeuticstargetedinhibitionofbace1andelucidationofintricatemolecularcrosstalkwithtauoligomersandbacterialgingipains AT othukebodeghe insilicoprofilingofneemlimonoidsandgutmicrobiomemetabolitesforalzheimerstherapeuticstargetedinhibitionofbace1andelucidationofintricatemolecularcrosstalkwithtauoligomersandbacterialgingipains AT olurantieolaiya insilicoprofilingofneemlimonoidsandgutmicrobiomemetabolitesforalzheimerstherapeuticstargetedinhibitionofbace1andelucidationofintricatemolecularcrosstalkwithtauoligomersandbacterialgingipains AT babatunjieoyinloye insilicoprofilingofneemlimonoidsandgutmicrobiomemetabolitesforalzheimerstherapeuticstargetedinhibitionofbace1andelucidationofintricatemolecularcrosstalkwithtauoligomersandbacterialgingipains |